Annexin Pharmaceuticals AB (ANNX) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.716x

Based on the latest financial reports, Annexin Pharmaceuticals AB (ANNX) has a cash flow conversion efficiency ratio of -0.716x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-10.33 Million ≈ $-1.11 Million USD) by net assets (Skr14.42 Million ≈ $1.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Annexin Pharmaceuticals AB to measure how many days the company can operate on defensive assets alone.

Annexin Pharmaceuticals AB - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Annexin Pharmaceuticals AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Annexin Pharmaceuticals AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Annexin Pharmaceuticals AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Burford Capital Limited LSE:BUR	0.048x
Peppermint Innovation Ltd AU:PIL	0.030x
Digitree Group S.A WAR:DTR	0.140x
Zenith Steel Pipes & Industries Limited NSE:ZENITHSTL	-0.005x
Danish Aerospace Company A/S CO:DAC	0.428x
CCH Holdings Ltd Ordinary Shares NASDAQ:CCHH	N/A
Koszalinskie Przedsiebiorstwo Przemyslu Drzewnego SA WAR:KPD	0.062x
RUGBY RESOURCES LTD F:64O	N/A

Annual Cash Flow Conversion Efficiency for Annexin Pharmaceuticals AB (2015–2025)

The table below shows the annual cash flow conversion efficiency of Annexin Pharmaceuticals AB from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Annexin Pharmaceuticals AB market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr24.93 Million ≈ $2.68 Million	Skr-36.92 Million ≈ $-3.97 Million	-1.481x	+59.57%
2024-12-31	Skr13.71 Million ≈ $1.48 Million	Skr-50.23 Million ≈ $-5.41 Million	-3.663x	-58.77%
2023-12-31	Skr18.81 Million ≈ $2.02 Million	Skr-43.40 Million ≈ $-4.67 Million	-2.307x	-68.98%
2022-12-31	Skr30.15 Million ≈ $3.24 Million	Skr-41.16 Million ≈ $-4.43 Million	-1.365x	-41.68%
2021-12-31	Skr46.73 Million ≈ $5.03 Million	Skr-45.02 Million ≈ $-4.85 Million	-0.964x	+49.27%
2020-12-31	Skr20.64 Million ≈ $2.22 Million	Skr-39.20 Million ≈ $-4.22 Million	-1.899x	+15.17%
2019-12-31	Skr11.49 Million ≈ $1.24 Million	Skr-25.73 Million ≈ $-2.77 Million	-2.239x	-213.04%
2018-12-31	Skr39.85 Million ≈ $4.29 Million	Skr-28.50 Million ≈ $-3.07 Million	-0.715x	+55.27%
2017-12-31	Skr24.44 Million ≈ $2.63 Million	Skr-39.08 Million ≈ $-4.21 Million	-1.599x	-150.32%
2016-12-31	Skr15.57 Million ≈ $1.68 Million	Skr-9.95 Million ≈ $-1.07 Million	-0.639x	-101.75%
2015-12-31	Skr-137.00K ≈ $-14.74K	Skr-5.01 Million ≈ $-539.37K	36.584x	--

About Annexin Pharmaceuticals AB

ST:ANNX Sweden Biotechnology

Market Cap

$9.12 Million

Skr84.71 Million SEK

Market Cap Rank

#27300 Global

#598 in Sweden

Share Price

Skr12.00

Change (1 day)

-1.64%

52-Week Range

Skr12.00 - Skr32.20

All Time High

Skr37.00